Immunotherapy Advances Will Serve Aging Demand Yet Face Regulatory Hurdles
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
11 Aug 25
Updated
16 Aug 25
AnalystHighTarget's Fair Value
US$120.00
77.3% undervalued intrinsic discount16 Aug
US$27.26
1Y
36.6%7D
21.3%